These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Shortridge KF, Zhou NN, Guan Y, Gao P, Ito T, Kawaoka Y, Kodihalli S, Krauss S, Markwell D, Murti KG, Norwood M, Senne D, Sims L, Takada A, Webster RG. Virology; 1998 Dec 20; 252(2):331-42. PubMed ID: 9878612 [Abstract] [Full Text] [Related]
5. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Veits J, Römer-Oberdörfer A, Helferich D, Durban M, Suezer Y, Sutter G, Mettenleiter TC. Vaccine; 2008 Mar 20; 26(13):1688-96. PubMed ID: 18291561 [Abstract] [Full Text] [Related]
6. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China. Connie Leung YH, Luk G, Sia SF, Wu YO, Ho CK, Chow KC, Tang SC, Guan Y, Malik Peiris JS. Vaccine; 2013 Aug 02; 31(35):3536-42. PubMed ID: 23791547 [Abstract] [Full Text] [Related]
8. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus. Swayne DE, Lee CW, Spackman E. Avian Pathol; 2006 Apr 02; 35(2):141-6. PubMed ID: 16595307 [Abstract] [Full Text] [Related]
9. Development and use of fowlpox vectored vaccines for avian influenza. Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, Audonnet JC, Mickle TR. Ann N Y Acad Sci; 2006 Oct 02; 1081():193-201. PubMed ID: 17135511 [Abstract] [Full Text] [Related]
10. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens. Jadhao SJ, Lee CW, Sylte M, Suarez DL. Vaccine; 2009 Oct 19; 27(44):6247-60. PubMed ID: 19686695 [Abstract] [Full Text] [Related]
11. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI. Vaccine; 2006 Nov 17; 24(47-48):6859-66. PubMed ID: 17050041 [Abstract] [Full Text] [Related]
13. Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics. Tian G, Zhang S, Li Y, Bu Z, Liu P, Zhou J, Li C, Shi J, Yu K, Chen H. Virology; 2005 Oct 10; 341(1):153-62. PubMed ID: 16084554 [Abstract] [Full Text] [Related]
14. Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Qiao CL, Yu KZ, Jiang YP, Jia YQ, Tian GB, Liu M, Deng GH, Wang XR, Meng QW, Tang XY. Avian Pathol; 2003 Feb 10; 32(1):25-32. PubMed ID: 12745375 [Abstract] [Full Text] [Related]
15. [Influenza type A (H5N1) virus infection]. Engin A. Mikrobiyol Bul; 2007 Jul 10; 41(3):485-94. PubMed ID: 17933264 [Abstract] [Full Text] [Related]
19. Use of avian influenza vaccination in Hong Kong. Ellis TM, Sims LD, Wong HK, Wong CW, Dyrting KC, Chow KW, Leung C, Peiris JS. Dev Biol (Basel); 2006 Jul 10; 124():133-43. PubMed ID: 16447504 [Abstract] [Full Text] [Related]
20. Application of new vaccine technologies for the control of transboundary diseases. Swayne DE. Dev Biol (Basel); 2004 Jul 10; 119():219-28. PubMed ID: 15742632 [Abstract] [Full Text] [Related] Page: [Next] [New Search]